Akebia Therapeutics Inc
AKBA2.040USD
+0.030+1.49%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
536.61MMarket Cap
LossP/E TTM
More Details of Akebia Therapeutics Inc Company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Akebia Therapeutics Inc Info
Ticker SymbolAKBA
Company nameAkebia Therapeutics Inc
IPO dateMar 20, 2014
CEOMr. John P. Butler
Number of employees181
Security typeOrdinary Share
Fiscal year-endMar 20
Address245 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02142
Phone16178712098
Websitehttps://akebia.com/
Ticker SymbolAKBA
IPO dateMar 20, 2014
CEOMr. John P. Butler
Company Executives of Akebia Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.25%
The Vanguard Group, Inc.
5.84%
State Street Investment Management (US)
3.02%
Geode Capital Management, L.L.C.
2.29%
Alerce Investment Management, L.P.
2.17%
Other
80.43%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.25%
The Vanguard Group, Inc.
5.84%
State Street Investment Management (US)
3.02%
Geode Capital Management, L.L.C.
2.29%
Alerce Investment Management, L.P.
2.17%
Other
80.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.20%
Investment Advisor/Hedge Fund
13.14%
Hedge Fund
7.04%
Research Firm
4.02%
Individual Investor
3.57%
Private Equity
2.17%
Bank and Trust
0.20%
Pension Fund
0.16%
Venture Capital
0.06%
Other
52.45%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
299
117.08M
44.16%
+9.43M
2025Q2
284
112.41M
42.78%
+33.09M
2025Q1
280
111.54M
42.50%
+30.68M
2024Q4
258
78.54M
36.08%
+7.41M
2024Q3
257
64.16M
30.51%
-2.18M
2024Q2
248
61.31M
29.27%
-7.52M
2024Q1
290
61.37M
29.36%
-12.30M
2023Q4
289
58.79M
31.24%
-20.79M
2023Q3
300
57.28M
30.45%
-25.18M
2023Q2
308
56.18M
30.22%
-26.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
16.58M
6.25%
+2.61M
+18.71%
Jun 30, 2025
The Vanguard Group, Inc.
14.61M
5.51%
+1.93M
+15.18%
Jun 30, 2025
State Street Investment Management (US)
8.00M
3.02%
+1.19M
+17.50%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.07M
2.29%
+1.04M
+20.75%
Jun 30, 2025
Alerce Investment Management, L.P.
5.75M
2.17%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.17%
+5.75M
--
Dec 31, 2024
Morgan Stanley & Co. LLC
4.34M
1.64%
+2.26M
+108.33%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
1.58%
+188.60K
+4.71%
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.53M
1.33%
+1.07M
+43.71%
Jun 30, 2025
MPM BioImpact LLC
2.89M
1.09%
+2.89M
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco Biotechnology & Genome ETF
2.36%
Invesco NASDAQ Future Gen 200 ETF
0.42%
ALPS Medical Breakthroughs ETF
0.42%
SPDR S&P Biotech ETF
0.34%
Federated Hermes MDT Small Cap Core ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
iShares Micro-Cap ETF
0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.09%
View more
Invesco Biotechnology & Genome ETF
Proportion2.36%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.42%
ALPS Medical Breakthroughs ETF
Proportion0.42%
SPDR S&P Biotech ETF
Proportion0.34%
Federated Hermes MDT Small Cap Core ETF
Proportion0.2%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.18%
iShares Micro-Cap ETF
Proportion0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.11%
Vanguard US Momentum Factor ETF
Proportion0.1%
Fidelity Enhanced Small Cap ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
